{
  "meta": {
    "title": "Thyroid_Parathyroid_Disorders_Part-2",
    "url": "https://brainandscalpel.vercel.app/thyroid-parathyroid-disorders-part-2-de3c8051.html",
    "scrapedAt": "2025-11-29T18:24:48.472Z"
  },
  "questions": [
    {
      "id": 54029,
      "choices": [
        {
          "id": 215585,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neck exploration under general anesthesia. </span></span></span></p>"
        },
        {
          "id": 215586,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Check Mg levels. </span></span></span></p>"
        },
        {
          "id": 215587,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neck Ultrasound to look for parathyroids. </span></span></span></p>"
        },
        {
          "id": 215588,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Add Cinacalcet.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 64-year-old female with PHPT underwent parathyroidectomy. On POD 4, she experiences persistent hypocalcemia with low PTH levels, requiring continuous IV calcium infusion to maintain S.Ca. Which of the following is the most appropriate next step?</span></span></span></p>",
      "unique_key": "Q4521906",
      "question_audio": null,
      "question_video": null,
      "map_id": 25623,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Check Mg levels.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Persistent hypocalcemia with low PTH levels after parathyroidectomy suggests hypoparathyroidism. However, hypomagnesemia is an important cause of hypoparathyroidism post-op and cause hypocalcemia by impairing PTH secretion and action. Therefore, checking magnesium levels is the most appropriate next step, as correcting hypomagnesemia may resolve the hypocalcemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Neck exploration under general anesthesia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This is invasive and usually done if there is persistent hyperparathyroidism. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Neck Ultrasound to look for parathyroids:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Will not be providing any useful information in a post-op patient with hypoparathyroidism. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Add Cinacalcet:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Cinacalcet is a calcimimetic that lowers PTH,&nbsp;which is already low in this patient.&nbsp;It would be inappropriate and potentially worsen hypocalcemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient who has persistent hypocalcemia and low PTH levels post-parathyroidectomy, the most appropriate next step is to <strong>check magnesium levels</strong>.</span></span></span></p>",
      "correct_choice_id": 215586,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54028,
      "choices": [
        {
          "id": 215581,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Observation </span></span></span></p>"
        },
        {
          "id": 215582,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Parathyroidectomy </span></span></span></p>"
        },
        {
          "id": 215583,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cinacalcet </span></span></span></p>"
        },
        {
          "id": 215584,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bisphosphonates</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 43-year-old male presents with a serum calcium of 11.2 mg/dL (normal 8.5-10.5) and a parathyroid hormone (PTH) level of 110 pg/mL (normal 15-70 pg/mL). He is otherwise asymptomatic, has normal renal function, and his dual-energy X-ray absorptiometry (DXA) scan is within normal limits. What is the most appropriate management?</span></span></p>",
      "unique_key": "Q8082764",
      "question_audio": null,
      "question_video": null,
      "map_id": 25622,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Parathyroidectomy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s elevated serum calcium and PTH levels are indicative of primary hyperparathyroidism (PHPT). Although he is currently asymptomatic, guidelines recommend parathyroidectomy for patients under 50 with PHPT, especially when serum calcium levels are above the upper limit of normal. This is because even asymptomatic PHPT can lead to long-term complications such as osteoporosis, nephrolithiasis, and cardiovascular disease.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Indications for parathyroidectomy in asymptomatic PHPT:</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">&nbsp;</span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum calcium (above normal) &gt;1 mg/dL.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal Creatinine clearance &lt;60 mL/min or 24-h Urinary calcium &gt; 400 mg/d + increased stone risk by biochemical stone risk analysis or Presence of stones or nephrocalcinosis.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skeletal BMD by DXA: T score &lt;&ndash;2.5 or Vertebral fracture.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Age &lt;50.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Observation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;While observation might be considered in elderly patients with mild PHPT,&nbsp;it is not appropriate for a young,&nbsp;asymptomatic patient with elevated S.Ca levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Cinacalcet:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Cinacalcet is a calcimimetic that can lower PTH and calcium levels.&nbsp;However,&nbsp;it is not a first-line treatment for PHPT and is generally reserved for patients who are not surgical candidates or who have persistent PHPT post-surgery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Bisphosphonates:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Bisphosphonates can help to prevent bone loss but do not address the underlying cause of hyperparathyroidism,&nbsp;which is excessive PTH secretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most appropriate management for a 43-year-old male with primary hyperparathyroidism (PHPT), elevated serum calcium, and PTH levels is <strong>parathyroidectomy</strong>.</span></span></span></p>",
      "correct_choice_id": 215582,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53967,
      "choices": [
        {
          "id": 215337,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">8.0 mg/dL </span></span></span></p>"
        },
        {
          "id": 215338,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">8.3 mg/dL </span></span></span></p>"
        },
        {
          "id": 215339,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">8.5 mg/dL </span></span></span></p>"
        },
        {
          "id": 215340,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">9.0 mg/dL</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old woman with chronic kidney disease presents with muscle cramps and tingling in her fingers. Her serum calcium is 7.7 mg/dL (normal: 8.5-10.5 mg/dL) and serum albumin is 3.0 g/dL (normal range: 3.5-5.0 g/dL). What is her corrected calcium level?</span></span></p>",
      "unique_key": "Q3260716",
      "question_audio": null,
      "question_video": null,
      "map_id": 25561,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) 8.5 mg/dL</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corrected calcium is calculated using the following formula:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corrected calcium (mg/dL) = Measured calcium (mg/dL) + 0.8 x (4.0 - Albumin [g/dL])</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In this case:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corrected calcium = 7.5 + 0.8 x (4.0 - 3.0) = 7.7 + 0.8 = 8.5 mg/dL</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therefore, the patient&#39;s corrected calcium level is 8.5 mg/dL, which is within the normal range.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">To calculate the corrected calcium level in patients with low serum albumin, use the formula: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corrected calcium (mg/dL) = Measured calcium (mg/dL) + 0.8 x (4.0 - Albumin [g/dL])</span></span></p>",
      "correct_choice_id": 215339,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54023,
      "choices": [
        {
          "id": 215561,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTH (Parathyroid Hormone) </span></span></span></p>"
        },
        {
          "id": 215562,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcium</span></span></span></p>"
        },
        {
          "id": 215563,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FGF-23 (Fibroblast Growth Factor 23) </span></span></span></p>"
        },
        {
          "id": 215564,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1,25 (OH)2D (Calcitriol)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following stimulates the production of 1,25(OH)2D (Calcitriol) by activating 1&alpha;-hydroxylase in the kidneys?</span></span></p>",
      "unique_key": "Q4067794",
      "question_audio": null,
      "question_video": null,
      "map_id": 25617,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) PTH (Parathyroid Hormone)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTH is a major stimulator of 1&alpha;-hydroxylase, the enzyme responsible for converting 25-hydroxyvitamin D to the active form 1,25-dihydroxyvitamin D (calcitriol) in the kidneys. This process is crucial for calcium homeostasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Calcium:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;High calcium levels actually suppress 1&alpha;-hydroxylase activity,&nbsp;decreasing calcitriol production.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. FGF-23:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;FGF-23 also suppresses 1&alpha;-hydroxylase activity and reduces calcitriol levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. 1,25 (OH)2D (Calcitriol):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Calcitriol acts through a negative feedback loop to inhibit its own production by suppressing 1&alpha;-hydroxylase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Summary:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D basics: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cutaneous production of cholecalciferol is reduced by melanin and sunblocks.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">25 (OH)D [calcidiol] is the major circulating form (formed in the liver by 25 hydroxylase). t1/2 </span><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> 2-3 weeks (88% of 25 (OH)D is bound to Vitamin D binding protein)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2nd hydroxylation occurs in kidney (PCT) by 1&alpha;-hydroxylase forming 1,25 (OH)2D (Calcitriol) &ndash; the active from. 1&alpha;-hydroxylase is hormonally regulated &ndash;</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><em><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stimulated by:</span></u></em><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> PTH and low phosphate.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><em><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibited by:</span></u></em><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ca, FGF-23 &amp; 1,25 (OH)2D (Calcitriol).</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1&alpha;-hydroxylase is also present in other cells (keratinocytes, placenta, macrophages), but not hormonally regulated.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inactivation of vitamin D metabolites occurs through 24-hydroxylation.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Actions of 1,25(OH)2D [calcitriol]:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">VDR forms heterodimer with retinoid X receptor, inducing target gene expression.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">VDR is expressed in various cells and tissues. Effects of VDR -</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intestine: Increased calcium absorption by inducing calbindin 9K, TRPV5, TRPV6. </span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bone: Regulates osteoblasts (increases osteocalcin, osteopontin, RANKL and FGF23).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Parathyroid: Reduces PTH production. </span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Others: Antiproliferative effects (keratinocytes, breast ca cells, prostate ca cells).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Effects of VDR on hair follicle is ligand (Vitamin D) independent!!</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTH (Parathyroid Hormone) stimulates the production of 1,25(OH)2D (Calcitriol) by activating 1&alpha;-hydroxylase in the kidneys.</span></span></span></p>",
      "correct_choice_id": 215561,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53996,
      "choices": [
        {
          "id": 215453,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypernatremia </span></span></span></p>"
        },
        {
          "id": 215454,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypocalcemia </span></span></span></p>"
        },
        {
          "id": 215455,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperphosphatemia </span></span></span></p>"
        },
        {
          "id": 215456,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypophosphatemia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old man with chronic alcoholism was started in IV dextrose. He develops cardiac arrhythmias, seizures, and rhabdomyolysis. Which of the following electrolyte disturbances is most likely responsible for her clinical deterioration?</span></span></p>",
      "unique_key": "Q3089794",
      "question_audio": null,
      "question_video": null,
      "map_id": 25590,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Hypophosphatemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s clinical presentation is consistent with refeeding syndrome, a potentially life-threatening condition that can occur in severely malnourished individuals after reintroducing nutrition. Refeeding syndrome is characterized by shifts in fluids and electrolytes, with hypophosphatemia being the most prominent and dangerous abnormality.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypophosphatemia can lead to a range of complications, including:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac arrhythmias:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Due to impaired myocardial function and energy metabolism.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Seizures:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Due to altered neuronal excitability and cerebral energy depletion.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rhabdomyolysis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Due to muscle cell breakdown from insufficient energy production.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hypernatremia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hypernatremia (high sodium) is not a typical feature of refeeding syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Hypocalcemia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hypocalcemia (low calcium) can occur in refeeding syndrome, but it is less common and less severe than hypophosphatemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hyperphosphatemia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hyperphosphatemia (high phosphate) is the opposite of what is seen in refeeding syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Refeeding syndrome, commonly occurring in severely malnourished individuals after reintroducing nutrition, is characterized by hypophosphatemia, which can lead to cardiac arrhythmias, seizures, and rhabdomyolysis.</span></span></span></p>",
      "correct_choice_id": 215456,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54026,
      "choices": [
        {
          "id": 215573,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN1 </span></span></span></p>"
        },
        {
          "id": 215574,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HRPT2 </span></span></span></p>"
        },
        {
          "id": 215575,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CASR</span></span></span></p>"
        },
        {
          "id": 215576,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">GCM2</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following genetic mutations is usually associated with parathyroid carcinoma?</span></span></span></p>",
      "unique_key": "Q9771638",
      "question_audio": null,
      "question_video": null,
      "map_id": 25620,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) HRPT2</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HRPT2 (CDC73) is a tumor suppressor gene. Inactivating mutations in both copies of this gene are found in the majority of parathyroid carcinomas. These mutations lead to the loss of parafibromin, a protein that normally helps regulate cell growth and division.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HRPT2 mutations are also associated HPT-JT (Hyperparathyroidism-Jaw tumour). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. MEN1:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Mutations in this gene are associated with multiple endocrine neoplasia type 1 (MEN1),&nbsp;a syndrome that can include parathyroid adenomas but rarely carcinoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. CASR:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Mutations in this gene cause familial hypocalciuric hypercalcemia (FHH),&nbsp;a benign condition unrelated to parathyroid cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. GCM2:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Mutations in this gene are associated with <em><u>non-syndromic</u></em> familial isolated hyperparathyroidism (FIHP),&nbsp;which is characterized by benign parathyroid tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HRPT2 mutations are usually associated with parathyroid carcinoma.</span></span></p>",
      "correct_choice_id": 215574,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54019,
      "choices": [
        {
          "id": 215545,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Burosumab </span></span></span></p>"
        },
        {
          "id": 215546,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teplizumab </span></span></span></p>"
        },
        {
          "id": 215547,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teprotumumab </span></span></span></p>"
        },
        {
          "id": 215548,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atezolizumab</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following monoclonal antibodies has been approved for X-linked hypophosphatemia (XLH)?</span></span></p>",
      "unique_key": "Q5744026",
      "question_audio": null,
      "question_video": null,
      "map_id": 25613,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Burosumab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Burosumab is a monoclonal antibody that targets and inhibits fibroblast growth factor 23 (FGF23). Excess FGF23 is the primary driver of XLH, causing renal phosphate wasting and impaired bone mineralization. By inhibiting FGF23, burosumab can effectively increase serum phosphate levels, improve bone mineralization, and alleviate symptoms associated with XLH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Burosumab also have shown promise in TIO (tumor induced osteoamalacia) &ndash; which also occurs due to production of FGF-23 by certain tumours. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Teplizumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This monoclonal antibody (CD3) is used in the treatment of type 1 diabetes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Teprotumumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This monoclonal antibody (IGF-1r) is used in the treatment of thyroid eye disease (Graves&#39; ophthalmopathy).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Atezolizumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This monoclonal antibody (PD-L1) is used in the treatment of certain types of cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Burosumab is a monoclonal antibody approved for X-linked hypophosphatemia (XLH).</span></span></p>",
      "correct_choice_id": 215545,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54024,
      "choices": [
        {
          "id": 215565,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1,25 (OH)2 D [calcitriol] levels are often normal.</span></span></span></p>"
        },
        {
          "id": 215566,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Expansion of the proliferating zone is seen in rickets. </span></span></span></p>"
        },
        {
          "id": 215567,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Looser&#39;s zones seen in osteomalacia occur near large arteries. </span></span></span></p>"
        },
        {
          "id": 215568,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proximal myopathy can occur.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presents with fatigue and bone pain. Laboratory findings reveal low serum calcium, elevated parathyroid hormone (PTH), and low 25-hydroxyvitamin D [calcidiol] levels. Which of the following statements regarding this patient&#39;s condition is incorrect?</span></span></p>",
      "unique_key": "Q5310963",
      "question_audio": null,
      "question_video": null,
      "map_id": 25618,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Expansion of the proliferating zone is seen in rickets.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Three layers of chondrocytes are present in the normal growth plate: the reserve zone, the proliferating zone, and the hypertrophic zone. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rickets is characterized by impaired apoptosis and expansion of the hypertrophic chondrocyte layer (leading to expansion of the growth plate). Hence, chondrocytes cannot be replaced by osteoblasts, it leads to defective bone mineralization. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. 1,25 (OH)2 D (calcitriol) levels are often normal:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;In severe vitamin D deficiency,&nbsp;there is a compensatory increase in PTH,&nbsp;which stimulates 1&alpha;-hydroxylase activity and can maintain normal calcitriol levels despite the deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Looser&#39;s zones seen in osteomalacia occur near large arteries:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;These radiolucent lines,&nbsp;also known as pseudofractures,&nbsp;are characteristic of osteomalacia and are often found adjacent to large arteries. These are often long, but only a few mm wide and common in scapula, pelvis and femoral neck. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Proximal myopathy can occur:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Muscle weakness,&nbsp;particularly in the proximal muscles,&nbsp;is a common symptom of severe vitamin D deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Summary: Vitamin D deficiency &ndash;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Causes:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Poor sunlight exposure, poor intake/malabsorption, increased demand (barbiturates, phenytoin, rifampin, nephrotic syndrome), impaired activation (liver or kidney disease, hypoparathyroidism, FGF23 excess) or resistance (VDR mutations).</span></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Genetic causes: VDDR type I (1&alpha;-hydroxylase mutations, can be responsive to calcitriol) &amp; VDDR type 2 (VDR mutations, has alopecia and resistant to calcitriol).</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clinical Manifestations:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> &darr; S.Ca, &uarr; PTH (leading to &darr;PO4 and &uarr;ALP), proximal myopathy, and increased CV mortality.</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rickets in children before epiphyseal fusion.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Osteomalacia in adults. </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diagnosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Serum 25(OH)D level &ndash; best screening test.</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D sufficiency is defined as &gt;50 nmol/L (&gt;20 ng/mL).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&lt;37 nmol/L (&lt;15 ng/mL) &ndash; can lead to &uarr; PTH &amp; &uarr; ALP.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment:</span></strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">RDA: 600 IU/d (1-70 years) and 800 IU/d (&gt;70 years). But up to 40000 IU/d is safe !</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Severe deficiency: Repletion (50000 IU/week for 3-12 weeks) followed by maintenance therapy (800 IU/d).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If 1&alpha;-hydroxylation is defective, use metabolites not requiring activation (calcitriol, doxercalciferol, alfacalcidol).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Monitor treatment with serum and urinary calcium measurements. Target 24-h urinary Ca = 100&ndash;250 mg/d (&gt; 250mg/d should lead to reduction in dosage).</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Expansion of the proliferating zone is not seen in rickets; it is the hypertrophic zone that is expanded.</span></span></span></p>",
      "correct_choice_id": 215566,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53968,
      "choices": [
        {
          "id": 215341,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduced S. Ig levels can increase total serum calcium levels.</span></span></span></p>"
        },
        {
          "id": 215342,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DCT is the major site for active calcium reabsorption in the kidney.</span></span></span></p>"
        },
        {
          "id": 215343,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CaSR in the cortical TAL in the kidney works independent of Vit D and PTH.</span></span></span></p>"
        },
        {
          "id": 215344,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Passive intestinal absorption is non saturable.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following regarding calcium homeostasis is NOT true?</span></span></p>",
      "unique_key": "Q4472985",
      "question_audio": null,
      "question_video": null,
      "map_id": 25562,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Reduced S. Ig levels can increase total serum calcium levels.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alterations in serum protein concentrations directly affect the total blood </span></span></span><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">calcium concentration but the ionized calcium remains normal. Calcium (total) hence, should be corrected with regards to albumin and Ig concentrations in the blood.&nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corrected calcium (mg/dL) = Measured calcium (mg/dL) + 0.8 x (4.0 - Albumin [g/dL]) OR</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corrected calcium (mg/dL) = Measured calcium (mg/dL) + 0.5 x (Ig deficit)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><em><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intestinal Calcium absorption:</span></em></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">RDA: 1000-1200mg/d</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Passive absorption: 5% of intake, nonsaturable. Reason for hypercalcemia with large intakes of calcium (e.g., Milk Alkali Syndrome).</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Active absorption: 20-70% of intake, via <u>TRPV6</u> channels, regulated by 1,25(OH)2D.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Requires gastric acid, especially for calcium carbonate supplements.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal Calcium regulation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">8-10 g/day filtered by glomeruli, 2-3% excreted in urine.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proximal tubule: 65% reabsorbed passively.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cortical thick ascending limb (cTAL): 20% reabsorbed passively (Paracellin-1).</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CaSR works independent of Vit D and PTH, inhibits Paracellin-1. </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DCT: 10% reabsorbed actively, via TRPV5, stimulated by PTH.</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazide diuretics reduce calciuresis.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sodium loads or loop diuretics increase calciuresis.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>DCT is the major site for active calcium reabsorption in the kidney:</strong> True. Via TRPV5.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>CaSR in the cortical TAL in the kidney works independent of Vit D and</strong> <strong>PTH:</strong> CaSR senses only Ca and Mg . PTH or Vit D does NOT exert control on CaSR. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Passive intestinal absorption is non saturable:</strong> True. Main reason for hypercalcemia with large intakes of calcium (e.g., Milk Alkali Syndrome).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alterations in serum protein concentrations, such as albumin and immunoglobulin (Ig) levels, directly affect the total serum calcium concentration but do not change the ionized calcium levels. Corrected calcium should be calculated in relation to albumin and Ig concentrations.</span></span></span></p>",
      "correct_choice_id": 215341,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53995,
      "choices": [
        {
          "id": 215449,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Majority of phosphorus absorption in intestine is Vitamin D dependent.</span></span></span></p>"
        },
        {
          "id": 215450,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum levels are best measured in fasting state.</span></span></span></p>"
        },
        {
          "id": 215451,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTH and FGF23 increase Na-Pi transporter activity in the PCT.</span></span></span></p>"
        },
        {
          "id": 215452,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Concentration of phosphorus is more in ECF compared to ICF. </span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following regarding Phosphorus homeostasis is correct?</span></span></p>",
      "unique_key": "Q2775567",
      "question_audio": null,
      "question_video": null,
      "map_id": 25589,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Serum levels are best measured in fasting state.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Distribution: 85% (bone) &amp; 15% (ECF and ICF, exists as H2PO4- or NaHPO4-). Phosphorus is the most abundant intracellular anion. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Absorption: Widely available in food, absorbed efficiently (65%) even without vitamin D.</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Active transport via Na+/PO42- co-transporters (NaPi-2b), stimulated by 1,25(OH)2D, increases absorption to 85-90%.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low serum phosphate stimulates 1,25(OH)2D synthesis.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum levels: Normal = 2.5-4.5 mg/dL</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vary by up to 50% daily due to food intake and circadian rhythm (nadir at 7-10 AM).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carbohydrate (e.g., IV dextrose) administration can lower serum phosphate.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Measurements are best done in the fasting state.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Regulation: Primarily by renal handling (tubular reabsorption)</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Filtered load = 4-6 g/day &amp; Fractional excretion = 10-15%.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proximal tubule: Main site of regulation, via NaPi-2a and NaPi-2c co-transporters (PTH and FGF23 reduce transporter levels, increasing phosphate excretion).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dietary phosphate restriction rapidly lowers urinary phosphate (possibly via FGF23).</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Majority of phosphorus absorption in intestine is Vitamin D dependent:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Phosphorus is absorbed efficiently (65%) even without vitamin D. Vit D increases absorption to 85-90%.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. PTH and FGF23 increase Na-Pi transporter activity in the PCT:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> PTH and FGF23 reduce Na-Pi levels, increasing phosphate excretion. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Concentration of phosphorus is more in ICF compared to ECF:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Phosphorus is the most abundant intracellular anion. ECF concentrations and amount are generally lower. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum phosphorus levels are best measured in the fasting state due to variations caused by food intake and circadian rhythms.</span></span></span></p>",
      "correct_choice_id": 215450,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54017,
      "choices": [
        {
          "id": 215537,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phosphate cannot be administered IV.</span></span></span></p>"
        },
        {
          "id": 215538,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypocalcemia, if present must be corrected first.</span></span></span></p>"
        },
        {
          "id": 215539,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase dose of phosphate if hypercalcemic.</span></span></span></p>"
        },
        {
          "id": 215540,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperglycemia is common.</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old chronic alcoholic developed refeeding syndrome and is about to get IV phosphate replacement. Which of the following is true?</span></span></p>",
      "unique_key": "Q7369071",
      "question_audio": null,
      "question_video": null,
      "map_id": 25611,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Hypocalcemia, if present must be corrected first</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In refeeding syndrome, aggressive administration of carbohydrates can lead to a shift of phosphate, potassium, and magnesium into cells, resulting in a drop in their serum levels. Since phosphate binds to calcium, it&#39;s crucial to correct hypocalcemia before administering IV phosphate to prevent further hypocalcemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Measurement of Ca and PO4 every 6-12h is recommended in patients receiving IV phosphate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Phosphate cannot be administered IV:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Phosphate can be administered IV,&nbsp;usually as sodium or potassium phosphate salts. Less severe hypophosphatemia (1.5&ndash;2.5 mg/dL) can be treated with oral phosphate (750&ndash;2000 mg/d as elemental phosphorus) but higher doses can cause bloating and diarrhea.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Increase the dose of phosphate if hypercalcemic:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Reduce dose of phosphate by 50% if the patient is hypercalcemic (serum Ca-PO4 product must be &lt;50 mg2/dL2 to reduce the risk of heterotopic calcification).</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduction of dose is also recommended in patients with renal dysfunction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hyperglycemia is common:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Hypoglycemia is common due to increased glucose entry and utilization by tissues. Hence concurrent dextrose administration can be considered (especially in those at risk of hypoglycemia). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In refeeding syndrome, hypocalcemia, if present, must be corrected before administering IV phosphate to prevent further hypocalcemia.</span></span></span></p>",
      "correct_choice_id": 215538,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54020,
      "choices": [
        {
          "id": 215549,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mg is primarily absorbed in the jejunum.</span></span></span></p>"
        },
        {
          "id": 215550,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D can increase Mg absorption.</span></span></span></p>"
        },
        {
          "id": 215551,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Majority of Mg is reabsorbed in the PCT.</span></span></span></p>"
        },
        {
          "id": 215552,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mg reabsorption is inhibited by hypercalcemia.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following regarding Magnesium (Mg) homeostasis is incorrect?</span></span></p>",
      "unique_key": "Q4198759",
      "question_audio": null,
      "question_video": null,
      "map_id": 25614,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Majority of Mg is reabsorbed in the PCT.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only 20% of filtered magnesium is reabsorbed in the proximal tubule, whereas 60% is reclaimed in the cTAL and another 5&ndash;10% in the DCT. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Magnesium reabsorption in the cTAL occurs via a paracellular route that requires both a lumen-positive potential, created by NaCl reabsorption, and tight-junction proteins encoded by members of the Claudin gene family. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Magnesium reabsorption in the cTAL is increased by PTH but inhibited by hypercalcemia or hypermagnesemia, both of which activate the CaSR in this nephron segment. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Mg is primarily absorbed in the jejunum:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This is true,&nbsp;although some absorption also occurs in the ileum. Usual absorption is 30-40% but can increase to 70% during deficiency states. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Vitamin D can increase Mg absorption:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This is true,&nbsp;although the mechanism is not fully understood.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Mg reabsorption is inhibited by hypercalcemia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This is also true.&nbsp;Magnesium reabsorption in the cTAL is increased by PTH but inhibited by hypercalcemia or hypermagnesemia, both of which activate the CaSR in this nephron segment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The majority of magnesium is reabsorbed in the cortical thick ascending limb (cTAL) of the kidney.</span></span></span></p>",
      "correct_choice_id": 215551,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54021,
      "choices": [
        {
          "id": 215553,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Protective against Digitalis toxicity.</span></span></span></p>"
        },
        {
          "id": 215554,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Co-existent hypocalcemia is common.</span></span></span></p>"
        },
        {
          "id": 215555,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IM MgSO4 is as effective as IV MgSO4.</span></span></span></p>"
        },
        {
          "id": 215556,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D deficiency, if present should be corrected with calcitriol.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 20-year-old man who is a known case of Gitelman&rsquo;s syndrome presents with tetany. On evaluation his serum Mg level is 0.6 g/dL (normal: 1.7-2.4 mg/dL). Which of the following is true?</span></span></span></p>",
      "unique_key": "Q5936515",
      "question_audio": null,
      "question_video": null,
      "map_id": 25615,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Co-existent hypocalcemia is common.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tetany and a low serum magnesium level (0.6 mg/dL) strongly suggest severe hypomagnesemia in this case. Hypomagnesemia can cause impaired synthesis of calcitriol, cellular resistance to PTH and decreased synthesis of PTH (at levels &lt; 1mg/dL). Hence co-existent hypocalcemia is common.<br />\r\n\t(IV Mg replacement, hence can increase PTH secretion and can worsen pre-existing hypophosphatemia </span><span style=\"font-family:Wingdings\">&rarr;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> can lead to rhabdomyolysis). </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Co-existent hypokalemia is also common as hypomagnesemia results in renal potassium wasting. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Protective against Digitalis toxicity:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Hypomagnesemia actually increases the risk of digitalis toxicity (ECG abnormalities in hypomagnesemia: Prolonged PR or QT intervals, T-wave flattening or inversion, and ST straightening).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. IM MgSO4 is as effective as IV MgSO4:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;For IV use, MgCl2 is generally preferred.<br />\r\nIV MgSO4 is inferior because sulfate anions may bind calcium in serum and urine and aggravate hypocalcemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Use of IM MgSO4 is discouraged - the injections are painful and provide relatively little magnesium (2 mL of 50% MgSO4 supplies only 4 mmol). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Vitamin D deficiency, if present, should be corrected with calcitriol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Vitamin D deficiency frequently coexists with hypomagnesemia and should be treated with calcidiol (but not with calcitriol, which may impair tubular magnesium reabsorption, possibly via PTH suppression by acting on VDR in the parathyroid gland).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Co-existent hypocalcemia is common in patients with severe hypomagnesemia, such as in Gitelman&#39;s syndrome.</span></span></span></p>",
      "correct_choice_id": 215554,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54022,
      "choices": [
        {
          "id": 215557,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rituximab.</span></span></span></p>"
        },
        {
          "id": 215558,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cetuximab.</span></span></span></p>"
        },
        {
          "id": 215559,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ustekinumab.</span></span></span></p>"
        },
        {
          "id": 215560,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Burosumab. </span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of following drugs is most likely to cause hypomagnesemia?</span></span></p>",
      "unique_key": "Q4020406",
      "question_audio": null,
      "question_video": null,
      "map_id": 25616,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Cetuximab.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). EGFR signaling is necessary for the proper function of magnesium channels in the kidney. Inhibition of EGFR by cetuximab can lead to renal magnesium wasting and subsequent hypomagnesemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Rituximab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Targets CD20 on B cells and is not associated with hypomagnesemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ustekinumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Targets interleukin-12 and -23 and is not associated with hypomagnesemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Burosumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Targets FGF23 and is used to treat X-linked hypophosphatemia; it does not cause hypomagnesemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Summary:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Important causes of hypomagnesemia &ndash;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Impaired absorption:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Vit D deficiency, PPIs, malabsorption, <em><u>TRPM6 mutations</u></em> (rare).</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increases intestinal losses:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Vomiting, diarrhea, fistulas. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Impaired renal absorption:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <em><u>Syndromes</u></em> (Barrtter&rsquo;s, Gitelman&rsquo;s), TIN, <em><u>drugs</u></em> (diuretics, cisplatin, cyclosporine, aminoglycosides, foscarnet, pentamidine &amp; <em><u>cetuximab</u></em>) &amp; others (hypercalcemia, severe hypophosphatemia)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ECF to ICF</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <em><u>Refeeding</u></em>, insulin, catecholamines.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cetuximab is most likely to cause hypomagnesemia among the listed drugs.</span></span></span></p>",
      "correct_choice_id": 215558,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54025,
      "choices": [
        {
          "id": 215569,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intermittent PTH increases bone mass. </span></span></span></p>"
        },
        {
          "id": 215570,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTHR1 is the principal receptor for PTH and PTHrP. </span></span></span></p>"
        },
        {
          "id": 215571,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTHrP acts primarily via autocrine/paracrine pathways. </span></span></span></p>"
        },
        {
          "id": 215572,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recombinant human calcitonin is useful in hypercalcemic states.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the incorrect statement among the following:</span></span></p>",
      "unique_key": "Q2482100",
      "question_audio": null,
      "question_video": null,
      "map_id": 25619,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Recombinant human calcitonin is useful in hypercalcemic states.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcitonin from salmon is 10&ndash;100x more potent than mammalian forms &ndash; is used therapeutically to lower serum calcium in hypercalcemic states. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Intermittent PTH increases bone mass:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This is true and is the basis for the use of PTH analogs (teriparatide and abaloparatide) in the treatment of osteoporosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. PTHR1 is the principal receptor for PTH and PTHrP:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Both hormones share the same receptor,&nbsp;which explains their similar physiological effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. PTHrP acts primarily via autocrine/paracrine pathways:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;PTHrP mainly acts locally on the cells that produce it or on nearby cells,&nbsp;rather than having systemic effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Summary: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTH Structure and Physiology:</span></strong></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">84-amino-acid peptide (first 34 amino acids being crucial for its function).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acts on bone, kidney, and indirectly on the intestine to &uarr; serum calcium.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Regulation: PTH release inhibited by calcium and vitamin D (and vice versa).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Continuous exposure to high PTH leads to bone resorption, while intermittent administration increases bone mass.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTH acts on osteoblasts, which indirectly activate osteoclasts (via RANKL) for bone resorption.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTH assays should ideally measure only the full-length, biologically active form.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTHrP Structure and Physiology:</span></strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTHrP and PTH share structural and functional homology and bind to PTHR1 (activating mutations of PTHR1 results in Jansen&rsquo;s disease &ndash; hypercalcemia, short limbed dwarfism and cystic bone lesions with undetectable PTH)</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is produced in many cell types and mainly acts as a paracrine factor. PTHrP is important for bone development and other functions.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTHrP and its role in calcium homeostasis is limited to disease states (especially in humoral hypercalcemia of malignancy (HHM).</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcitonin:</span></strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&darr; bone resorption and &uarr; renal calcium clearance.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is of limited physiologic significance in humans. </span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Used as a tumor marker (MTC) and treatment for hypercalcemia and Paget&#39;s disease.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcitonin from salmon is 10&ndash;100x more potent than mammalian forms &ndash; is used therapeutically to lower serum calcium in hypercalcemic states. </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recombinant human calcitonin is not useful in hypercalcemic states; salmon calcitonin is used therapeutically.</span></span></span></p>",
      "correct_choice_id": 215572,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54027,
      "choices": [
        {
          "id": 215577,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Parathyroid carcinoma </span></span></span></p>"
        },
        {
          "id": 215578,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multiple endocrine neoplasia type 1 (MEN1) </span></span></span></p>"
        },
        {
          "id": 215579,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Monoclonal outgrowth within hyperplastic parathyroid glands </span></span></span></p>"
        },
        {
          "id": 215580,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D resistance</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old man with CKD stage 4 presents with persistent hypercalcemia and elevated PTH levels despite treatment with vitamin D analogs. Which of the following is the most likely cause of his persistent hyperparathyroidism?</span></span></span></p>",
      "unique_key": "Q5749568",
      "question_audio": null,
      "question_video": null,
      "map_id": 25621,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Monoclonal outgrowth within hyperplastic parathyroid glands</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) is common (SHPT occurs due to impaired phosphate excretion and decreased production of active vitamin D, leading to hypocalcemia and a compensatory increase in PTH). </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Initially, this involves hyperplasia of all four parathyroid glands. However, over time, a monoclonal outgrowth of parathyroid cells can occur within these hyperplastic glands, leading to autonomous PTH secretion and persistent hyperparathyroidism. This is often referred to as <em><u>tertiary hyperparathyroidism</u></em> and is a common cause of persistent hyperparathyroidism in CKD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Parathyroid carcinoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Although possible,&nbsp;parathyroid carcinoma is less likely in this scenario as it is relatively rare.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Multiple endocrine neoplasia type 1 (MEN1):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;MEN1 is a hereditary syndrome that can cause primary hyperparathyroidism (PHPT).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Vitamin D resistance:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Can cause SHPT,&nbsp;but unlikely in the given clinical context. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Monoclonal outgrowth within hyperplastic parathyroid glands is the most likely cause of persistent hyperparathyroidism in a CKD patient.</span></span></span></p>",
      "correct_choice_id": 215579,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54030,
      "choices": [
        {
          "id": 215589,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tc99m Sestamibi SPECT.</span></span></span></p>"
        },
        {
          "id": 215590,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">24-hour urinary calcium.</span></span></span></p>"
        },
        {
          "id": 215591,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DXA spine and femur.</span></span></span></p>"
        },
        {
          "id": 215592,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bisphosphonates.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 71-year-old male with abdominal pain underwent an ultrasound (USG) that showed renal stones. His serum calcium (S.Ca) is 12.3 mg/dL (normal 8.5-10.5) and his parathyroid hormone (PTH) is 135 pg/mL (normal 15-70). What should be done next?</span></span></span></p>",
      "unique_key": "Q6939475",
      "question_audio": null,
      "question_video": null,
      "map_id": 25624,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Tc99m Sestamibi SPECT</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s elevated serum calcium and PTH levels strongly suggest primary hyperparathyroidism (PHPT). The presence of renal stones further supports this diagnosis. Tc99m Sestamibi SPECT is the most appropriate next step as it is a highly sensitive imaging modality for localizing parathyroid adenomas, which are the most common cause of PHPT.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Surgical Management of Hyperparathyroidism:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Two approaches: Conventional parathyroidectomy (neck exploration under GA) and minimally invasive parathyroidectomy (preferred since can be done outpatient with LA).</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Minimally invasive surgery utilizes preoperative localization. Tools for localization -</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">99mTc sestamibi scans (Addition of SPECT or 4D CT is recommended for accuracy)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4D CT + USG. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intraoperative PTH monitoring (fall in PTH by &gt; 50% post adenoma removal).</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multi-gland hyperplasia needs identification and removal/partial removal of all glands.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If no abnormal glands are found in the neck, further exploration with specialized imaging and venous sampling may be needed.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. 24-hour urinary calcium:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;While this can help assess calcium metabolism,&nbsp;it is not the immediate next step in diagnosing the cause of the patient&#39;s hypercalcemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. DXA spine and femur:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;DXA scans assess bone density and can reveal osteoporosis,&nbsp;a potential complication of PHPT.&nbsp;However,&nbsp;the priority is to confirm the diagnosis of PHPT and localize the parathyroid adenoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Bisphosphonates:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Bisphosphonates are used to treat osteoporosis,&nbsp;a potential consequence of PHPT,&nbsp;but not the primary hyperparathyroidism itself.&nbsp;They are not indicated at this stage of diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a 71-year-old male with suspected primary hyperparathyroidism and renal stones, the next step is <strong>Tc99m Sestamibi SPECT</strong> to localize the parathyroid adenoma.</span></span></span></p>",
      "correct_choice_id": 215589,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54031,
      "choices": [
        {
          "id": 215593,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D intoxication </span></span></span></p>"
        },
        {
          "id": 215594,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin A intoxication </span></span></span></p>"
        },
        {
          "id": 215595,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sarcoidosis </span></span></span></p>"
        },
        {
          "id": 215596,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-small cell lung cancer (NSCLC)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following conditions causing hypercalcemia is least likely to respond to glucocorticoid therapy?&nbsp;</span></span></span></p>",
      "unique_key": "Q1522890",
      "question_audio": null,
      "question_video": null,
      "map_id": 25625,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Non-small cell lung cancer (NSCLC)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glucocorticoids work by reducing the production of 1,25-dihydroxyvitamin D (calcitriol) by activated macrophages and decreasing intestinal calcium absorption. They are effective in treating hypercalcemia caused by:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D intoxication:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Excess vitamin D leads to increased intestinal calcium absorption,&nbsp;which can be countered by glucocorticoids.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin A intoxication:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Glucocorticoids can counteract the bone resorption caused by excess vitamin A.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sarcoidosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Activated macrophages in granulomas produce excess calcitriol,&nbsp;and glucocorticoids reduce this production.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">However, glucocorticoids are not typically effective in treating hypercalcemia caused by <strong>non-small cell lung cancer (NSCLC)</strong>. This type of hypercalcemia is usually due to the production of parathyroid hormone-related protein (PTHrP) by the tumor, which glucocorticoids do not inhibit.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Vitamin D intoxication:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Glucocorticoids are a standard treatment for this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Vitamin A intoxication:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Glucocorticoids are effective in treating hypercalcemia related to vitamin A intoxication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Sarcoidosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Glucocorticoids are a first-line treatment for hypercalcemia caused by sarcoidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The condition causing hypercalcemia that is least likely to respond to glucocorticoid therapy is <strong>non-small cell lung cancer (NSCLC)</strong>.</span></span></p>",
      "correct_choice_id": 215596,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54032,
      "choices": [
        {
          "id": 215597,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IV Fluids</span></span></p>"
        },
        {
          "id": 215598,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">s.c Denosumab</span></span></p>"
        },
        {
          "id": 215599,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IV Zoledronic acid </span></span></span></p>"
        },
        {
          "id": 215600,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IV Calcitonin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with breast cancer presents with dehydration and a serum calcium of 17 mg/dL. Which of the following is not a useful therapy?</span></span></p>",
      "unique_key": "Q4081590",
      "question_audio": null,
      "question_video": null,
      "map_id": 25626,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) IV Calcitonin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While calcitonin can initially lower serum calcium levels, its effect is transient due to tachyphylaxis (rapidly diminishing response to repeated doses). In a case of severe hypercalcemia (calcium &gt;14 mg/dL), such as in this patient with breast cancer, more potent and longer-lasting therapies are required.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. IV Fluids:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Aggressive hydration with isotonic saline is essential to restore intravascular volume and promote renal calcium excretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. s.c Denosumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Denosumab,&nbsp;a monoclonal antibody targeting RANKL,&nbsp;is a potent inhibitor of osteoclast activity and bone resorption,&nbsp;making it effective in malignancy-associated hypercalcemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. IV Zoledronic Acid:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Zoledronic acid,&nbsp;a bisphosphonate,&nbsp;is another potent inhibitor of bone resorption and is commonly used in the management of hypercalcemia of malignancy.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-184606.jpg\" style=\"height:596px; width:1000px\" /><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-184633.jpg\" style=\"height:451px; width:1000px\" /></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with severe hypercalcemia due to malignancy, <strong>IV Calcitonin</strong> is not as useful due to its transient effect and development of tachyphylaxis.</span></span></span></p>",
      "correct_choice_id": 215600,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54033,
      "choices": [
        {
          "id": 215601,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary hyperparathyroidism</span></span></p>"
        },
        {
          "id": 215602,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Milk-alkali syndrome</span></span></p>"
        },
        {
          "id": 215603,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sarcoidosis</span></span></p>"
        },
        {
          "id": 215604,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D intoxication</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old woman with a history of osteoporosis presents with fatigue, nausea, and polyuria. Labs reveal hypercalcemia, metabolic alkalosis, and elevated creatinine. Which of the following is the most likely cause of her symptoms?</span></span></p>",
      "unique_key": "Q5055399",
      "question_audio": null,
      "question_video": null,
      "map_id": 25627,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Milk-alkali syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of hypercalcemia, metabolic alkalosis, and renal failure in this patient is highly suggestive of milk-alkali syndrome. This condition is caused by excessive intake of calcium and absorbable alkali (milk/calcium carbonate), which is common in osteoporosis.<br />\r\nRisk is higher if the patient has co-existing renal failure (due to reduced calcium excretion).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Primary hyperparathyroidism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;While it can cause hypercalcemia,&nbsp;it is not typically associated with metabolic alkalosis and renal impairment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Sarcoidosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Can cause hypercalcemia but is usually associated with granulomatous inflammation and elevated 1,25-dihydroxyvitamin D levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Vitamin D intoxication:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;While it can cause hypercalcemia,&nbsp;it is not usually associated with metabolic alkalosis and renal impairment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most likely cause of hypercalcemia, metabolic alkalosis, and renal impairment in an elderly woman with osteoporosis is <strong>milk-alkali syndrome</strong>.</span></span></p>",
      "correct_choice_id": 215602,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54034,
      "choices": [
        {
          "id": 215605,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start IV Zoledronate.</span></span></span></p>"
        },
        {
          "id": 215606,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start Calcium and calcitriol supplements.</span></span></span></p>"
        },
        {
          "id": 215607,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IV fluids and forced diuresis.</span></span></span></p>"
        },
        {
          "id": 215608,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Administer IV sodium bicarbonate.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with perioral numbness and tingling one day after total thyroidectomy. Which of the following is the most appropriate management?</span></span></p>",
      "unique_key": "Q8297239",
      "question_audio": null,
      "question_video": null,
      "map_id": 25628,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Start Calcium and calcitriol supplements.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Perioral numbness and tingling after a thyroidectomy are classic signs of hypocalcemia, which is a common complication due to inadvertent removal or damage to the parathyroid glands during surgery. Neck surgery is the most common cause of acquired hypoparathyroidism and it is usually transient. Initial treatment of choice is calcium and calcitriol supplements.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment of Hypoparathyroidism:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D and calcitriol (1,25(OH)2D) combined with high oral calcium intake. Need higher Vitamin D doses compared to euparathyroid patients. </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcitriol (0.5-1 mcg/day) is often preferred over vitamin D due to faster clearance.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Maintain blood calcium at lower end of normal range to avoid hypercalciuria, nephrocalcinosis, and kidney stones.</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazide diuretics can help lower urine calcium in hypoparathyroid patients on a low-Na diet.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTH replacement therapy: Full-length PTH(1-84) is now approved for hypoparathyroidism. If full length PTH is unavailable, one can use teriparatide (synthetic form containing PTH [1-34]).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Start IV Zoledronate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Zoledronic acid is a bisphosphonate used to treat hypercalcemia by inhibiting bone resorption.&nbsp;It would worsen hypocalcemia in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. IV fluids and forced diuresis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This is used to treat hypercalcemia,&nbsp;not hypocalcemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Administer IV sodium bicarbonate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Sodium bicarbonate is used to correct metabolic acidosis and has no role in treating hypocalcemia. In fact it can worsen hypokalemia by causing alkalosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most appropriate management for hypocalcemia presenting with perioral numbness and tingling post-thyroidectomy is <strong>starting calcium and calcitriol supplements</strong>.</span></span></p>",
      "correct_choice_id": 215606,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54035,
      "choices": [
        {
          "id": 215609,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pseudopseudohypoparathyroidism (PPHP) </span></span></span></p>"
        },
        {
          "id": 215610,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pseudohypoparathyroidism type 1A (PHP1A) </span></span></span></p>"
        },
        {
          "id": 215611,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pseudohypoparathyroidism type 1B (PHP1B) </span></span></span></p>"
        },
        {
          "id": 215612,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pseudohypoparathyroidism type 2 (PHP2)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 10-year-old child presents with short stature, round face, obesity, shortened fourth and fifth metacarpals, hypocalcemia, and hyperphosphatemia. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q1494916",
      "question_audio": null,
      "question_video": null,
      "map_id": 25629,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Pseudohypoparathyroidism type 1A (PHP1A)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The child&#39;s presentation is characteristic of Albright&#39;s hereditary osteodystrophy (AHO), which is a key feature of PHP1A. AHO includes short stature, round face, obesity, brachydactyly (shortened metacarpals/metatarsals), and sometimes intellectual disability. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The laboratory findings of hypocalcemia and hyperphosphatemia, along with elevated PTH levels, are consistent with PTH resistance, a hallmark of pseudohypoparathyroidism. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pseudopseudohypoparathyroidism (PPHP):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Individuals with PPHP have AHO features but normal calcium,&nbsp;phosphate,&nbsp;and PTH levels.&nbsp;They do not exhibit hormone resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Pseudohypoparathyroidism type 1B (PHP1B):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;While PHP1B also presents with hypocalcemia and hyperphosphatemia,&nbsp;it is less likely to be associated with the full spectrum of AHO features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pseudohypoparathyroidism type 2 (PHP2):</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;PHP2 is characterized by hypocalcemia and hyperphosphatemia with normal urinary cAMP response to PTH,&nbsp;but it does not typically present with AHO features.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-190718.jpg\" style=\"height:499px; width:1000px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The child&#39;s presentation with short stature, round face, obesity, shortened fourth and fifth metacarpals, hypocalcemia, and hyperphosphatemia is characteristic of Albright&#39;s hereditary osteodystrophy (AHO), which is associated with PHP1A.</span></span></span></p>",
      "correct_choice_id": 215610,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54036,
      "choices": [
        {
          "id": 215613,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polyostotic fibrous dysplasia </span></span></span></p>"
        },
        {
          "id": 215614,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Caf&eacute;-au-lait spots</span></span></span></p>"
        },
        {
          "id": 215615,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypofunctioning endocrinopathy </span></span></span></p>"
        },
        {
          "id": 215616,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased FGF23</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is false regarding McCune Albright Syndrome ?</span></span></p>",
      "unique_key": "Q4120213",
      "question_audio": null,
      "question_video": null,
      "map_id": 25630,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Hypofunctioning endocrinopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">McCune Albright Syndrome (MAS) is a sporadic disorder due to activating GNAS1 mutations. It is more common in girls and it is characterized by a triad of:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polyostotic fibrous dysplasia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Abnormal bone growth with replacement of bone marrow by fibrous tissue. This is due to failure of differentiation of mesenchymal cells to osteoblasts. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Caf&eacute;-au-lait spots:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Light brown skin macules with irregular borders.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperfunctioning endocrinopathy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Overactive endocrine glands,&nbsp;most commonly leading to precocious puberty (others &ndash; thyrotoxicosis, Cushing&rsquo;s syndrome)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note that fibrous dysplasia is also a sporadic disorder with equal incidence in both sexes. Monostotic form is common (affects long bones) and usually diagnosed in adults. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Polyostotic fibrous dysplasia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This is a hallmark of MAS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Caf&eacute;-au-lait spots:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;These are another characteristic feature of MAS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Increased FGF23:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Polyostotic lesions can lead to elevated FGF23 levels, contributing to phosphate wasting and hypophosphatemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">McCune Albright Syndrome (MAS) is characterized by hyperfunctioning endocrinopathy, not hypofunctioning. It includes polyostotic fibrous dysplasia, caf&eacute;-au-lait spots, and increased FGF23.</span></span></span></p>",
      "correct_choice_id": 215615,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54037,
      "choices": [
        {
          "id": 215617,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alendronate </span></span></span></p>"
        },
        {
          "id": 215618,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Risedronate </span></span></span></p>"
        },
        {
          "id": 215619,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ibandronate </span></span></span></p>"
        },
        {
          "id": 215620,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Zoledronic acid</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man with osteoporosis and a history of peptic ulcer disease is considering treatment with oral bisphosphonates. Which of the following is most suitable for him?</span></span></span></p>",
      "unique_key": "Q2351628",
      "question_audio": null,
      "question_video": null,
      "map_id": 25631,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Risedronate</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Risedronate is available in a formulation that can be taken once weekly after breakfast. This is beneficial for patients with a history of peptic ulcer disease, as it avoids the need for taking medication on an empty stomach, which could potentially exacerbate their symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Alendronate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Requires administration on an empty stomach with water, which could be problematic for someone with peptic ulcer disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ibandronate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Also requires administration on an empty stomach and may not be well-tolerated in patients with a history of gastrointestinal issues.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Zoledronic acid:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is an intravenous bisphosphonate and does not address the specific concern of oral administration in a patient with peptic ulcer disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Risedronate can be taken after breakfast, which is beneficial for patients with a history of peptic ulcer disease, avoiding exacerbation of symptoms.</span></span></span></p>",
      "correct_choice_id": 215618,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54038,
      "choices": [
        {
          "id": 215621,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Zoledronate </span></span></span></p>"
        },
        {
          "id": 215622,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alendronate </span></span></span></p>"
        },
        {
          "id": 215623,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Denosumab </span></span></span></p>"
        },
        {
          "id": 215624,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raloxifene</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient had a hip fracture and was started on a bone protective agent. However, after 3 years of use, the patient lost follow-up and stopped therapy. Within 3 months of stopping treatment, the patient developed a new vertebral fracture. What is the drug that was likely given initially and stopped?</span></span></span></p>",
      "unique_key": "Q2972485",
      "question_audio": null,
      "question_video": null,
      "map_id": 25632,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Denosumab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Denosumab is a monoclonal antibody that inhibits RANKL, a key factor in osteoclast formation and function. While it is effective in reducing bone resorption and increasing bone density, its effects are rapidly reversible upon discontinuation. When denosumab is stopped, there can be a rebound increase in bone turnover and a significant loss of bone density, leading to an increased risk of fractures, particularly vertebral fractures, within a short period.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Zoledronate and Option B. Alendronate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These are bisphosphonates, which have a longer-lasting effect on bone remodeling than denosumab. While there can be a gradual loss of bone density after discontinuing bisphosphonates, it is not as rapid or dramatic as the rebound effect seen with denosumab.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Raloxifene:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a selective estrogen receptor modulator (SERM) with a milder effect on bone density compared to bisphosphonates and denosumab. Its discontinuation is not typically associated with a rapid increase in fracture risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Denosumab is associated with a rapid rebound increase in bone turnover and risk of fractures upon discontinuation, which explains the new vertebral fracture within three months of stopping the drug.</span></span></span></p>",
      "correct_choice_id": 215623,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54039,
      "choices": [
        {
          "id": 215625,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Strontium ranelate </span></span></span></p>"
        },
        {
          "id": 215626,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alendronate </span></span></span></p>"
        },
        {
          "id": 215627,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Romosozumab </span></span></span></p>"
        },
        {
          "id": 215628,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raloxifene</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old lady presented with a Colles&#39; fracture. She has diabetes and suffered from an MI 2 years ago and a stroke a year ago. Which of the following drugs would be the most appropriate for her osteoporosis treatment?</span></span></p>",
      "unique_key": "Q8953429",
      "question_audio": null,
      "question_video": null,
      "map_id": 25633,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Alendronate</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alendronate is a bisphosphonate, a class of drugs that are the first-line treatment for osteoporosis in most patients. It has been shown to reduce the risk of both vertebral and non-vertebral fractures, including Colles&#39; fractures. It is well-tolerated in most patients and has a good safety profile.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Strontium ranelate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Not available in the US and has a potential risk of cardiovascular events, which would be a concern in this patient with a history of MI and stroke.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Romosozumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While effective in reducing fractures, it has a higher cost and is usually reserved for patients with severe osteoporosis who have failed other treatments. Its safety profile in patients with cardiovascular disease is not yet fully established.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Raloxifene:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Raloxifene is a SERM that is primarily effective in reducing vertebral fractures and has limited data on preventing non-vertebral fractures like Colles&#39; fractures. Additionally, it carries a risk of thromboembolic events which might be a concern in this patient (but note that Raloxifene does not increase CV risk like HRT).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fracture reduction data:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-192229.jpg\" style=\"height:446px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alendronate is effective for reducing the risk of fractures and is generally well-tolerated, making it the most appropriate choice for a patient with a history of cardiovascular events and a Colles&#39; fracture.</span></span></span></p>",
      "correct_choice_id": 215626,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54040,
      "choices": [
        {
          "id": 215629,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">a-iii, b-iv,c-i, d-ii, e-v</span></span></span></p>"
        },
        {
          "id": 215630,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">a-iv, b-i,c-ii, d-v, e-iii&nbsp; </span></span></span></p>"
        },
        {
          "id": 215631,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">a-ii, b-i,c-iv, d-v, e-iii</span></span></span></p>"
        },
        {
          "id": 215632,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">a-iii, b-iv,c-i, d-v, e-ii</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Match the following bone protective drugs with their recommended durations of use:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-192447.jpg\" style=\"height:216px; width:700px\" /></span></span></p>",
      "unique_key": "Q5999106",
      "question_audio": null,
      "question_video": null,
      "map_id": 25634,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alendronate (a):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Typically used for up to <strong>5 years (iv)</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Zoledronate (b):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Typically used for up to <strong>3 years (i)</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Denosumab (c):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Used continuously, with long-term data supporting use for up to <strong>10 years (ii)</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Romosozumab (d):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Approved for use for up to <strong>1 year (v)</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abaloparatide (e):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Approved for up to <strong>2 years (iii)</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medications approved for use : </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alendronate (a): up to 5 years.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Zoledronate (b): up to 3 years.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Denosumab (c): up to 10 years.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Romosozumab (d): up to 1 year.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abaloparatide (e): up to 2 years.</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 215630,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54041,
      "choices": [
        {
          "id": 215633,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transdermal estrogen</span></span></span></p>"
        },
        {
          "id": 215634,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Equine estrogen with medroxyprogesterone </span></span></span></p>"
        },
        {
          "id": 215635,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raloxifene </span></span></span></p>"
        },
        {
          "id": 215636,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teriparatide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old depressed woman presents with a T-score of -2.8 on DEXA scan and severe hot flashes. She has a past history of hysterectomy 6 years ago. Which of the following would be the most suitable treatment for this patient to prevent fractures?</span></span></p>",
      "unique_key": "Q1179618",
      "question_audio": null,
      "question_video": null,
      "map_id": 25635,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Transdermal estrogen</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transdermal estrogen is the most suitable option because it addresses both the patient&#39;s osteoporosis (T-score -2.8) and severe hot flashes, a common symptom of menopause. Estrogen therapy is effective in preventing bone loss and reducing fracture risk in postmenopausal women, while also providing relief from menopausal symptoms.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Since the patient has undergone a hysterectomy, she does not require progestin to protect the endometrium, making estrogen-only therapy the preferred choice.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Risks and benefits of estrogen-progestin combinations is shown -</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-192756.jpg\" style=\"height:404px; width:700px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Equine estrogen with medroxyprogesterone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While this combination therapy is effective for osteoporosis and hot flashes, it is not necessary for women who have had a hysterectomy as it includes progestin, which is used to protect the endometrium in women with a uterus. Addition of progestin can potentially increase the risk of breast cancer as well. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Raloxifene:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Raloxifene is a selective estrogen receptor modulator (SERM) that can be used to prevent osteoporosis. However, it can worsen hot flashes and is not the ideal choice for this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Teriparatide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Teriparatide is an anabolic agent that stimulates bone formation. While effective for osteoporosis, it does not address menopausal symptoms and is generally reserved for patients with severe osteoporosis who have failed other treatments.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transdermal estrogen is effective for both osteoporosis and severe hot flashes, and since the patient has had a hysterectomy, she does not need progestin.</span></span></p>",
      "correct_choice_id": 215633,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}